Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 482 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR 10 Ways You Can Nurture A More Sustainable Garden June 18, 2021 Clinical Benefit and Safety of Encorafenib Plus Binimetinib in Treatment-Naïve and... June 12, 2023 FDA Approval Likely to Change Initial Treatment for Some People with... May 2, 2025 5 questions the NHS Workforce Plan for England needs to answer June 27, 2023 Load more HOT NEWS Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT... Maintenance Therapy Delays Cancer Growth for People With Advanced or Recurrent... The power of partnership – the unique alliance taking on brain... 6-Yr-Old With Cerebral Palsy Receives Dream Gift After Learning To Walk.
